throbber
0
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`
`September 09, 2015
`
`THIS IS TO CERTIFY THAT ANNEXED IS A TRUE COPY FROM THE
`RECORDS OF THIS OFFICE OF THE FILE WRAPPER AND CONTENTS
`OF:
`
`APPLICATION NUMBER: 08/416,673
`FILING DATE: April 07, 1995
`PATENT NUMBER: 5,665, 772
`ISSUE DATE: September 09,1997
`
`By Authority of the
`Under Secretary of Commerce for Intellectual Property
`and Director of the United States Patent and Trademark Office
`
`f/1 ~-
`
`M. TARVER
`Certifying Officer
`
`Par Pharm., Inc.
`Exhibit 1002
`Page 001
`
`

`
`- 37 -
`
`CLAIMS
`
`" .. ·
`
`0 , ••
`
`(I)
`
`0.....--
`
`24
`
`X is (H,H) or 0;
`
`Y is (H,OH) or 0;
`
`R 1 and R2 are independently selected from
`
`H, alkyl, thioalkyl, arylalkyl, hydroxyalkyl, dihydroxyalkyl,
`
`hydroxyalkylarylalkyl, dihydroxyalkylarylalkyl\alkoxyalkyl, acyloxyalkyl,
`\
`aminoalkyl, alkylaminoalkyl, alkoxycarbonylaminoalkyl, acylaminoalkyl,
`
`Par Pharm., Inc.
`Exhibit 1002
`Page 002
`
`

`
`,_
`.. -· WD 94/09010
`
`•
`
`-38-
`
`• PCT/EP93/02604
`
`~
`
`arylsulfonamidoalky~ allyl, dihydroxyalkylallyl, dioxolanylallyl,
`caralkoxyalkyl, and (R3~Si where each R3 is independently selected from~
`methyl, ethyl, isopropyl, ,!-butyl, and phenyl; wherein "alk-" or "alkyl" refers
`to cl-6 alkyl, branched or linear, preferably c;.3 alkyl, in which the carbon
`chain may be optionally interrupted by an ether (-0-) Hnksge; and
`
`R4 is m thy! or R~ and R 1 together fOim ~ alkylene;
`
`provided th R1 and Rz are not both H; and
`provided that here R1 is carbalkoxyalkyl or (RJ),Si. X andY are not both 0.
`
`2.
`
`Compounds ace
`· g to claim 1 selected from the following:
`1.
`40-0-Benzy:r rapamycin
`2.
`40-0-( 4 • -Hy
`xymethyl)benzyl-mpamycin
`3.
`40-0-[4'-(1,2-
`
`4.
`5.
`6.
`
`~Allyl-rapam cin
`40-0-[3'-(2,2-Dim yl-1.3-dioxolan-4{S)-yl)-prop-2'-en-l'-yl]-rapamycin
`(2'E. 4'5)-40-0-(4'
`'-Dihydroxypent-2'-en-1'-yl)-rapamycin
`40-0-(2-Hydroxy)etbo carbonylmethyl-rapamycin
`40-0-(2-Hydroxy)cthyl-
`9.
`40-0-(3-Hydroxy)propyl-
`amycin
`10. ~0-(6-Hydroxy)hexyl-rap yc:in
`11. 40-0-[2-(2-Hydroxy)ethoxy]e yl-rapamycin
`12. 4Q..0-[(3S)-2.2-Dimethyldioxol
`-3-yl]methyl-rapamycin
`13. ~0-[(25)-2,3-Dihyd:roxypzop-1- }-rapamycin
`14. 40-0-(2-Acetoxy)ethyl-rapamycin
`15. 40-0-(2-Nicotinoyloxy)ethyl-rapamycin
`16. 40-0-[2-(N-Morpholino )acetoxy]ethyl-~amycin
`
`7.
`
`8.
`
`\
`
`Par Pharm., Inc.
`Exhibit 1002
`Page 003
`
`

`
`' ;·
`.. , ..,....,\
`
`·Wd 94/09010
`;.....;'- ..
`
`•
`
`- 39-
`
`• . PCf/EP93/02604
`
`-~
`
`\
`17. 40-0-(2-N-Imidazolylacetoxy )ethyl-rapamycin
`18. 40-0-[2-(N-Methyl-N'-piperazinyl)acetoxy]ethyl-rapamycin
`19. 3~~-Desmethyl-39 ,40-0,0-ethylene-rapamycin
`20.
`(26R\ -26-Dihydro-40-0-(2-hydroxy)ethyl-rapamycin
`
`21.
`
`minoethyl)-rapamycin
`
`40-0-(2-~cetaminoethyl)-rapamycin
`
`22.
`23.
`24. 40-0-(2-N~~-namidoethyl)-rapamycin
`25. 40-0-(2-(N-
`ethyl-imidazo-2 '-ylcarbethoxamido)ethyl)-rapamycin
`26. 40-0-(2-Ethox ~arbon~laminoethy1)-rapamycin
`27. 40-0-(2-Tolylsul.fonamidoethyl)-rapamycin
`28. 40-0-[2 -( 4' ,5 '-D~boethoxy -I ',2' ,3 '-triazol-1 '-y I)-ethyl]-rapamycin
`
`3.
`
`4.
`
`5.
`
`6.
`
`7.
`
`8.
`
`Compounds according to clairp 1 where X andY are both 0, R2 isH, R4 is methyl,
`and R 1 is other than H.
`\
`.
`
`40-0-(2-Hydroxy)ethyl-rapamy\
`
`Compounds according to any one ~:!aims 1 through 4 obtained or obtainable by (i)
`reacting a rapamycin, deoxorapam~~:\.' or dihydrorapamycin (optionally in a(cid:173)
`protected form) with an organic radic' attached to a leaving group under suitable
`acidic or neutral reaction conditions, an
`(ii) optionally reducing the producL.
`
`A compound according to any one of clai
`
`1-5 for use as a pharmaceutical.
`
`A pharmaceutical composition comprising a co\pound according to any one of
`claims 1-5 together with a pharmaceutically ac\le diluent or carrier.
`
`Use of a compound according to claims 1-5 in the \ufacture of a medicament for
`
`Par Pharm., Inc.
`Exhibit 1002
`Page 004
`
`

`
`PCf/EP93/02604
`
`•
`
`- 40-
`
`or preventing any of the following conditions:
`
`(i)
`
`(ii)
`
`(iii)
`(iv) asthma,
`
`(v)
`
`ost disease.
`
`..
`
`(vi)
`roliferative disorders, or
`(vii) fungal infections,
`(viii) inflammation,
`
`having Mip or Mip-like factors, or
`
`9.
`
`Novel products, processes, and utilities substantially as described herein.
`
`Par Pharm., Inc.
`Exhibit 1002
`Page 005
`
`

`
`\W
`
`'·-~
`WORLD INTELLECTUAL PROPERTY ORGANIZATION'
`International Bureau
`'
`
`t1lt
`
`PCf
`INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCl)
`wo 94/09010
`
`(51) International Patent Oassification 5 :
`C07D 498/18, C07F 7/18
`A61K 31/435 I I C07D 498/18
`C07D 311:00, 273:00, 221:00
`
`(11) International Publication Number:
`
`At
`
`(43) International Publication Date:
`
`28 April 1994 (28.04.94)
`
`(21) International Application Number:
`
`PCT /EP93/02604
`
`(22) International Filing Date:
`
`24 September 1993 (24.09.93)
`
`(72) Inventors; and
`(75) Inventors/ Applicants {for US only) : COTTENS, Sylvain
`[CHICH]; In den Reben 12, CH-4108 Witterswil (CH).
`SEDRAN!, Richard [LU/CH]; Herrengrabenweg 15,
`CH-4054 Basle (CH).
`
`(30) Priority data:
`9221220.8
`
`9 October 1992 (09.1 0.92)
`
`GB
`
`(74) Common Representative: SANDOZ LTD.; Patents &
`Trademarks Div., Lichtstrasse 35, CH-4002 Basle (CH).
`
`(71) Applicant {for AT only): SANDOZ-ERFINDUNGEN
`VERWALTUNGSGESELLSCHAFT M.B.H. [AT/AT];
`Brunner Strasse 59, A-1230 Vienna (A 1).
`
`(71) Applicant (for DE only): SANDOZ-PATENT-GMBH [DE/ '
`DE]; Humboldstrasse 3,_D-79539 Lorrach (DE).

`
`(81) Designated States: AU, CA, CZ, FI, HU, JP, KR, NO, NZ,
`PL, RO, RU, SK, US, European patent (AT, BE, CH,
`DE, OK, ES, 'FR, GB, GR, IE, IT, LU, MC, NL, PT,
`SE).
`-
`
`(71) Applicant (for all designated States except AT DE US): SAN(cid:173)
`DOZ LTD. [CHICH]; Lichtstrasse 35, CH-4002 Basle
`(CH).
`
`Published
`With international search report.
`
`(54) Title: 0-ALKYLATED RAPAMYCIN DERIVATIVES AND THEIR USE, PARTICULARLY AS IMMUNOSUPPRES(cid:173)
`SANTS
`
`(57) Abstract
`
`Novel 0-alkylated derivatives of rapamycin of for-
`mula (1), especially 40-0-alkylated derivatives, are found a •a
`to have pharmaceutical utility, particularly as immunosup(cid:173)
`pressants.
`
`50.> , ...... ··
`~~0
`
`i 34
`
`1t
`
`0
`
`- -
`
`13
`
`15
`
`:
`
`(I)
`
`24
`
`Par Pharm., Inc.
`Exhibit 1002
`Page 006
`
`

`
`DECLARATION AND POWER OF ATTORNEY
`FOR UNITED STATES PATENT APPLICATION
`
`Case No.
`
`100-7932/PCT
`
`I
`
`~ '(
`
`'·"
`
`. '
`
`As a below named inventor, I hereby declare that:
`
`My residence, post office address and citizenship are as stated below next to my name,
`
`and
`
`I believe that I am the original, first and sole inventor (if only one name is listed below)
`or an original, first and joint inventor (if more than one name is listed below) of the subject
`
`matter which is claimed and for which a United States patent is sought on the invention
`
`entitled
`
`0-ALKYLATED RAPAMYCIN DERIVATIVES AND THEIR USE, PARTICULARLY
`AS IMMUNOSUPPRESSANTS
`
`the specification of which
`
`[ ]
`
`is attached hereto.
`
`[ ] was_ filed on
`
`19
`
`as application Serial No. 01
`
`and, if these brackets contain an X [
`
`], was amended on
`
`19
`
`[X] was filed as Patent Cooperation Treaty intemation application No. PCT/EP93/02604
`
`on September 24
`
`, 19 9 3
`
`, if these brackets contain an X [ ], was
`
`amended under Patent Cooperation Treaty Article 19 on
`
`and, if these brackets contain an X [
`[ ] entered the national stage in the United States and was accorded Serial No.
`
`] , was amended on
`
`' 19
`, 19
`
`on
`
`was amended on
`
`' 19
`
`, and if these brackets contain an X [
`
`I hereby state tha~. I have reviewed and understand the contents of the above-identified
`
`specifiction including the claims, as amended by any amendment(s) referred to above.
`I acknowledge my duty to disclose all information which is known by me to be material
`
`to patentability as defined in Title 37, Code of Federal Regulations, § 1.56.
`I hereby claim the benefit under Title 35, United States Code, § 119 of any foreign
`
`application(s) for patent or inventor's certificate indicated below and of any Patent
`
`Cooperation Treaty international application(s) designating at least one country other than the
`
`United States indicated below and have also identified any foreign application(s) for
`
`- 1 -
`
`Par Pharm., Inc.
`Exhibit 1002
`Page 007
`
`

`
`Case No. 100-7932/PCT
`
`patent or inventor's certificate and Patent Cooperation Treaty international application(s)
`designating at least one country other than the United States for the same subject matter and
`having a filing date before that of the application for said subject matter the priority of which
`is claimed:
`
`Country:
`
`Number:
`
`Filing Date:
`
`Great Britain
`
`9221220.8
`
`October 9, 1992
`
`Priority Claimed:
`
`[X] Yes[ ] No
`
`[ ] Yes[ ] No
`
`[ ] Yes[ ] No
`
`[ ] Yes[ ] No
`
`[
`
`] Yes[ ] No
`
`[ ] Yes[ ] No
`
`I hereby claim the .benefit under Title 35, United States Code, § 120 of any United
`States application(s) listed below and of any Patent Cooperation Treaty international
`application(s) designating the United States listed below and, insofar as the subject matter of
`each of the claims of this application is not disclosed in said prior app1ication(s) in the
`manner required by the first paragraph of Title 35, United States Code, § 112, I acknowledge
`my duty to disclose all information known to me to be material to patentability as defined in
`Title 37, Code of Federal Regulations, § 1.56 which became available between the filing
`date(s) of the prior application(s) and the national or Patent Cooperation Treaty international
`filing date of this application:
`
`Application
`
`Serial No.
`none
`
`Status (Pending,
`
`Abandoned, Patented)
`
`- 2 -
`
`Par Pharm., Inc.
`Exhibit 1002
`Page 008
`
`

`
`,--j
`
`'
`
`I hereby appoint the following:
`
`ROBERT S. HONOR
`THOMASO.MCGOVERN
`MELVYN M. KASSENOFF
`JOSEPH J. BOROVIAN
`DIANE E. FURMAN
`CARL W. BATTLE
`ANDREW N. PARFOMAK
`JOHN L. CHIATALAS
`CAROL A. LOESCHORN
`MICHAEL P. MORRIS
`THOMAS C. DOYLE
`
`Case No. 100-7932/PCT
`
`~&-No 22.801
`Reg. No. 25,741
`Reg. Nu.-26~89-
`Reg. No. 2.6.63-1-
`Reg. No.__31..-1.04-
`-Reg. No. 3Q73J(cid:173)
`Reg. No. 32 43 1
`Reg. No. 31,818
`_Reg No 35,590 -
`Reg. No. 34,513-
`Reg. No. 22,340
`
`/ /
`
`respectively and individually, as my attorneys and/or agents, with full power of substitution
`
`and revocation, to prosecute this application and to transact all business in the Patent and
`
`Trademarks Office connected therewith. Please address all communications to ROBERT S.
`HONOR, SANDOZ CORPORATION, 59 Route 10, East Hanover, New Jersey 07936-1080,
`
`whose telephone number is 201-503-8485.
`I hereby declare that all statements made herein of my own knowledge are true and that
`all statements made on information and belief are believed to be true; and further that these
`statements were made with the knowledge that willful false statements and the like so made
`
`are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United
`
`States Code and that such willful false statement may jeopardize the validity of the
`
`application or any patent issuing thereon.
`
`Sole inventor or
`first joint inventor:
`.... ;
`
`\
`
`Full name
`
`Sylvain Cottens
`
`·o
`/ _,..{)
`~·i·
`
`Signature
`Date
`Citizenship
`Residence
`
`fflat-~~ I~ ;13'1 \
`Switzerland
`CH-4108 Witterswil,
`In den Reben 12,
`Switzerland
`C-HX
`P.O. Address: same. as above. _
`
`IMPORTANT: Before this declaration is signed, the patent application (the specificateion, the claims and this
`declarations) must be read and understood by each person signing it, and no changes may be made in the
`application after this declaration has been signed.
`
`- 3 -
`
`Par Pharm., Inc.
`Exhibit 1002
`Page 009
`
`

`
`t ,-
`
`100-7932/PCT
`
`Case No.
`oD
`-z, _,....
`f[)i~~\~
`l g )_s-
`
`Second joint inventor,
`if any:
`
`Full name
`
`Richard Sedrani
`
`Signature
`Date
`Citizenship
`Residence
`
`~ill... 11
`Luxembourg
`Herrengrabenweg 15, CH-4054 Basle,
`C--H >(
`Switzerland
`P.O. Address :same as above
`
`Third joint inventor,
`if any:
`
`Fourth joint inventor,
`if any:
`
`Fifth joint inventor
`if any:
`
`Full name
`
`Signature
`Date
`Citizenship
`Residence
`
`P.O. Address:
`
`Full name
`
`Signature
`Date
`Citizenship
`Residence
`
`P.O. Address:
`
`Full name
`
`Signature
`Date
`Citizenship
`Residence
`
`P.O. Address:
`
`- 4-
`
`Par Pharm., Inc.
`Exhibit 1002
`Page 010
`
`

`
`f~ ··"
`
`.
`
`'
`
`DO/EO BIBLIOGRAPHIC DATA ENTRY
`
`SERIAL NUMBER:
`08 / 416673
`IA NUMBER:
`PCT/ £P93 / 02604
`FAMILY NAME:
`COTTENS
`GIVEN NAME:
`SYLVAIN
`PRIORITY CLAIMED (Y/NJ:
`Y
`NO BASIC FEE CY/N);
`N
`ATTORNEY DOCKET NUMBER:
`100-7932/PCT
`CORRESPONDENTS NAME/ADDRESS:
`ROBERT S. HONOR
`SANDOZ PATENT DEPT
`59 ROUTE 10
`E. HANOVER~ N.J. 07936-1080
`
`RECEIPT DATE:
`04 / 07 /
`IA FILING DATE:
`09 / 24 /
`DELAY WAIVED (Y/NJ:
`N
`DEMAND RECEIVED (Y/N)~
`Y
`PRIORITY DATE:
`10 / 09
`/
`US DESIGNATED ONLY CY/N):
`CtJUNTRY:
`
`APPLICATION TITLES:
`0-ALKLATED RAPAMYCIN DERIVATIVES AND THEIR US£, PARTICULARLY AS
`IMMUNOSUPPRESSENTS
`
`OK TO UPDATE? <Y OR NJ Y
`
`N
`
`95
`93 .
`
`•
`•
`•
`•
`t32 •
`EPX •
`•
`•
`•
`•
`•
`•
`•
`•
`•
`•
`•
`•
`•
`•
`•
`
`Par Pharm., Inc.
`Exhibit 1002
`Page 011
`
`

`
`BAR CODE
`
`lllllllllllllllllllllllllllllllll
`
`U.S. PATENT APPLICATION
`
`SERIAL NUMBER
`
`RUNG DATE
`
`ClASS
`
`GROUP ART UNIT
`
`08/416,673
`
`04/07/95
`
`514
`
`1205
`
`SYLVAIN COTTENS, WITTERSWIL, SWITZERLAND; RICHARD SEDRAN!, BASLE,
`SWITZERLAND.
`
`**CONTINUING DATA*********************
`VERIFIED
`THIS APPLN IS A 371 OF
`
`PCT/EP93/02604 09/24/93
`
`**FOREIGN/PCT APPLICATIONS************
`VERIFIED
`GREAT BRITAIN
`9221220.8
`
`10/09/92
`
`CHX
`
`0
`
`8
`
`1
`
`$1,090.00
`
`100-7932/PCT
`
`ALING FEE
`RECEIVED
`
`DOCKET NO.
`
`ROBERT S HONOR
`SANDOZ CORPORATION
`59 ROUTE 10
`EAST HANOVER NJ 07936-1080
`
`0-ALKYLATED RAPAMYCIN DERIVATIVES AND THEIR USE, PARTICULARLY AS
`IMMUNOSUPPRESSANTS
`
`This is to certify that annexed hereto is a true copy from the records of the United States
`Patent and Trademark Office of the application wh1ch is identified above.
`
`By authority of the
`COMMISSIONER OF PATENTS AND TRADEMARKS
`
`Date
`
`Certifying Officer
`
`Par Pharm., Inc.
`Exhibit 1002
`Page 012
`
`

`
`PATENT APPLICATION SERIAL Qo? / 4 1 6 6 7 3
`
`U.S. DEPARTMENT OF COMMERCE
`PATENT AND TRADEMAlUC OFFICE
`FEE RECORD SHEET
`
`---
`
`.::""?~·
`
`MS19049 04/12/95
`19039 05/22/95
`19040 05/22/95
`
`08416673
`08416673
`08416673
`
`.,.$~18086 05/30/95 08416673
`·-Hs19046 t0i23/9:i-Oa416673___ -
`
`PT0-1556
`(5/81)
`
`19-0134 190 960
`19--0134 190 960
`19-0134 190 970
`
`980.00CH
`980. OOCR ~
`,
`980.00CH VK-
`1 ~0 ~ "f
`. t~-0134 _ ~a~- 9?0" __ -~~~ooc~(J I$:
`
`19-om 190 · 968
`
`uo.oot\ift>
`
`Par Pharm., Inc.
`Exhibit 1002
`Page 013
`
`

`
`PATENT APPLICATION~~ 1 ~AMI NATION RECORD
`
`Effective -
`
`1 , 1994
`
`-~
`
`,
`', ~ :7r3;;Ft
`
`CLAIMS AS FILED - PART I
`(Column 1)
`
`12)
`
`SMALL ENTITY
`
`OR
`
`FOR
`
`NUMBER FILED
`
`NUMBER EXTRA
`
`RATE
`
`FEE
`
`BASIC FEE
`
`TOTAL CLAIMS
`
`INDEPENDENT CLAIMS
`
`4111&
`~,,
`
`0
`
`~~ /minus20=
`
`minus 3=
`
`*
`
`*
`
`MULTIPLE DEPENDENT CLAIM PRESENT
`
`* If the difference in column 1 is less than zero, enter ·o· in column 2
`
`-\
`
`365.00
`
`y
`
`{
`
`x$11=
`
`x38=
`
`+120=
`
`TOTAL
`
`OR
`
`OR
`
`OR
`
`OTHER THAN
`SMALL ENTITY
`
`RATE ~b
`
`f~V.VV
`
`x$22='
`
`,x76=
`OR
`OR +240= l:2¥V
`\&:~
`TOTAL ro::x JJ
`OTH~~~A~
`
`CLAIMS AS AMENDED - PART II
`(Column 1)
`(Column 2)
`CLAIMS
`REMAINING
`AFTER
`AMENDMENT
`
`HIGHEST
`NUMBER
`PREVIOUSLY
`PAID FOR
`
`(Column 3)
`
`PRESENT
`EXTRA
`
`*
`
`*
`
`Minus
`
`**
`
`Minus
`
`***
`
`=
`
`=
`
`c(
`1-
`z
`w
`:::E Total
`c
`z w
`:::E
`c(
`
`SMALL ENTITY OR
`
`SMALL ENTITY
`
`RATE
`
`x$11=
`
`x38=
`
`ADD I-
`TIONAL
`FEE
`
`RATE
`
`ADD I-
`TIONAL
`FEE
`
`OR x$22=
`
`OR
`
`x76=
`
`FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM
`
`(Column 1)
`
`'
`
`CLAIMS
`REMAINING
`AFTER
`AMENDMENT
`
`(Column 2)
`
`(Column 3)
`
`HIGHEST
`NUMBER
`PREVIOUSLY
`PAID FOR
`
`PRESENT
`EXTRA
`
`*
`
`*
`
`Minus
`
`**
`
`Minus
`
`***
`
`=
`
`=
`
`m
`1-
`z
`w
`:::E Total
`c
`z
`w
`:::E
`c(
`
`FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM
`
`(Column 1)
`
`CLAIMS
`REMAINING
`AFTER
`AMENDMENT
`
`(Column 2)
`
`(Column 3)
`
`HIGHEST
`NUMBER
`PREVIOUSLY
`PAID FOR
`
`PRESENT
`EXTRA
`
`RATE
`
`+120=
`TOTAL
`ADDIT. FEE
`
`RATE
`
`x$11=
`
`x38=
`
`+120=
`
`TOTAL
`ADDIT. FEE
`
`OR +240=
`
`TOTAL
`OR ADDIT. FEE
`
`ADD I-
`TIONAL
`FEE
`
`RATE
`
`ADD I-
`TIONAL
`FEE
`
`OR
`
`x$22=
`
`OR
`
`x76=
`
`OR +240=
`
`TOTAL
`OR ADDIT. FEE
`
`RATE
`
`ADD I-
`TIONAL
`FEE
`
`.
`ADD I-
`TIONAL
`FEE
`
`x$11=-
`
`x38=
`
`+120=
`
`OR x$22=
`
`OR x76=
`
`OR +240=
`
`0
`1-
`z
`w
`:::E Total
`c
`z
`w
`:::E
`c(
`
`*
`
`*
`
`Minus
`
`**
`
`Minus
`
`***
`
`=
`
`=
`
`FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM
`
`* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.
`TOTAL
`TOTAL
`** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20."
`OR ADDIT. FEE
`ADDIT. FEE
`***If the Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3."
`The Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.
`
`FORM PT0-875
`(Rev. 10/94)
`
`Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
`
`Par Pharm., Inc.
`Exhibit 1002
`Page 014
`
`

`
`W094/090JO •• ~-
`
`•'
`
`-
`
`0-ALKYLAIEQ RAPAMYCltLD.ERIYATIV.ES_ANO_T.HEIR_u.s.E., PARTICULARLY AS IMMUNO-
`,--SUPPRESSANTS
`. · ·


`-~
`;;··~ ~
`IV ,: .
`This invention comprises novel alkylated derivatives of rapamycin having
`pharmaceutical utility. especially as immunosuppressants.
`
`-
`
`Rapamycin is a known macrolide antibiotic produced by Streptomvces
`hve-roscopicus, having the structure depicted in Formula A:
`
`41
`
`36
`
`0
`
`0---
`
`5
`
`J
`
`(A)
`
`24
`
`See. e.g., McAlpine, J.B., et al., J. Antibiotics (1991) 44: 688; Schreiber, S.L., et al., J. Am.
`Chern. Soc. (1991) 113: 7433; US Patent No. 3 929 992. Rapamycin is an extremely
`
`Par Pharm., Inc.
`Exhibit 1002
`Page 015
`
`

`
`W094/09010
`
`PCf /EP93/02604
`
`- 2 -
`
`potent immunosuppressant and has also been shown to have antitumor and antifungal
`activity. Its utility as a pharmaceutical, however, is restricted by its very low and variable
`bioavailability as well as its high toxicity. Moreover, rapamycin is highly insoluble, making
`it difficult to formulate stable galenic compositions.
`
`It has now surprisingly been discovered that cenain novel derivatives of rapamycin
`(the Novel Compounds) have an improved pharmacologic profile over rapamycin, exhibit
`greater stability and bioavailability, and allow for greater ease in producing galenic
`formulations. The Novel Compounds are alkylated derivatives of rapamycin having the
`strucnrre of Formula I:
`
`41
`
`So ,, ....
`
`,,
`3
`: 34
`=
`2
`6 7~0
`II
`N
`8
`
`0
`
`(I)
`
`0---
`
`18
`
`20
`
`24
`
`--
`
`wherein
`
`3
`
`Par Pharm., Inc.
`Exhibit 1002
`Page 016
`
`

`
`W094/09010
`
`PCT /EP93/02604
`
`-3-
`
`X is (lUI) or 0;
`
`Y is (H.OH) or 0;
`
`R 1 and Rz are independently selected from
`H. alkyl~ thioalkyl, arylalkyl, hydroxyalkyl, dihydroxyalkyl.
`hydroxyalkylarylalkyl. dihydroxyalkylaxylalkyl. alkoxyali.."Y 1~ acyloxyalk:yl,
`aminoalkyl, alkylaminoalkyl. a!.koxycarbonylaminoalkyl, acylaminoalkyl,
`arylsulfonamidoalkyl, allyl, dihydroxyalkylallyl, dioxolanylallyl,
`carbalkoxyalk:yl. and (R3):3Si where each R3 is independently selected from H.
`methyl, ethyl, isopropyl, !-butyl. and phenyl; wherein "alk-" or "alkyl" refers
`to c;.6 alkyl, branched or linear preferably cl.l alkyl, in which the carbon
`chain may be optionally inren:u:pted by an ether ( -0-) linkage; and
`
`R4 is methyl, or R4 and R1 together fOim ~ alkylene;
`
`provided that R 1 and R~ are not both H; and
`provided that where R1 is (R3
`):3Si or carbalkoxyalkyl, X andY are not both 0.
`
`Preferred Novel Compounds include the following:
`40-0-Benzyl-rapamycin
`40-0-(4' -Hydroxymethyl)benzyl-rapamycin
`40-0-[ 4' -(1,2-Dihydroxyet:hyl)]benzyl-rapamycin
`40-0-Allyl-rapamycin
`40-0-[3'-(2,2-Dimethyl-1,3-dioxolan-4(S)-yl)-prop-2'-en-l'-yl]-rapamycin
`(2'E, 4tS)-40-0-(4' ,5'-Dihydroxypent-2'-en-1' -yl)-rapamycin
`40-0-(2-Hydroxy)eihoxycarbonylmerhyl-zapamycin
`40-0-(2-Hydroxy)ethyl-rapamycin
`
`1.
`
`2.
`
`3.
`
`4.
`5.
`6.
`
`7.
`
`8.
`
`Par Pharm., Inc.
`Exhibit 1002
`Page 017
`
`

`
`wo 94/09010
`
`PCf /EP93/02604
`
`- 4 -
`
`40-0-(3-Hydroxy )propyl-rapamycin
`40-0-(6-Hydroxy)hexyl-rapamycin
`40-0-[2-(2-Hydroxy)ethoxy]ethyl-rapamycin
`40-0-[(35)-2,2-Dimethyldioxolan-3-yl]methyl-rapamycin
`40-0-[(25)-2,3-Dihydroxyprop-1-yl]-rapamycin
`40-0-(2-Acetoxy)ethyl-rapamycin
`40-0-(2-Nicotinoyloxy)ethyl-rapamycin
`40-0-[2-(N-Morpholino)acetoxy]ethyl-rapamycin
`/ 40-0-(2-N-Imidazolylacetoxy)ethyl-rapamycin
`40-0-[2-(N-Methyl-N' -piperazinyl)acetoxy]ethyl-rapamycin
`39-0-Desmethyl-39,40-0,0-ethylene-rapamycin
`(26R)-26-Dihydro-40-0-(2-hydroxy)ethyl-rapamycin
`28-0-Methyl-rapamycin
`
`40-0-(2-Aminoethyl)-rapamycin
`40-0-(2-Acetaminoethyl)-rapamycin
`40-0-(2-Nicotinamidoethyl)-rapamycin
`40-0-(2-(N-Methyl-imidazo-2 '-y lcarbethoxamido )ethyl)-rapamycin
`40-0-(2-Ethoxycarbonylaminoethyl)-rapamycin
`40-0-(2-Tolylsulfonamidoethyl)-rapamycin
`40-0-[2-(4' ,5' -Dicarboethoxy-1 ',2' ,3 '-triazol-1 '-yl)-ethyl}-rapamycin
`
`9.
`
`10.
`
`11.
`
`12.
`
`13.
`
`14.
`
`15.
`
`16.
`
`17.
`
`18.
`
`19.
`
`20.
`
`21.
`
`22.
`
`23.
`
`24.
`
`25.
`
`26.
`
`27.
`
`28.
`
`The Novel Compounds for immunosuppressive use are preferably the
`40-0-substituted rapamycins where X andY are both 0, R2 isH, R4 is methyl, and R 1 is
`other than H; most preferably where R 1 is selected from hydroxyalkyl, hydroxyalkoxyalkyl,
`acylaminoalkyl, and aminoalkyl; especially 40-0-(2-hydroxy)ethyl-rapamycin, 40-0-(3-
`hydroxy)propyl-rapamycin, 40-0-[2-(2-hydroxy)ethoxy}ethyl-rapamycin, and
`40-0-(2-acetaminoethyl)-rapamycin).
`
`Preferably, a-substitution at C40 or 0,0-disubstitution at C28 and C40 is performed
`
`Par Pharm., Inc.
`Exhibit 1002
`Page 018
`
`

`
`wo 94/09010
`
`PCT /EP93/02604
`
`- 5 -
`
`according to the following general process: Rapamycin (or dihydro or deoxorapamycin) is
`reacted with an organic radical attached to a leaving group (e.g., RX where R is the organic
`radical, e.g., an alkyl, allyl, or benzyl moiety, which is desired- as the 0-substiruent, and X is
`the leaving group, e.g., CC13C(NH)O or CF3S03) under suitable reaction conditions,
`preferably acidic or neutral conditions, e.g., in the presence of an acid like
`oifluoromethanesulfonic acid, camphorsulfonic acid, p-toluenesulfonic acid or their
`respective pyridinium or substituted pyridinium salts when X is CC13C(NH)O or in the
`presence of a base like pyridine, a substituted pyridine, diisopropylethylamine or
`pentamethylpiperidine when X is CF3S03•
`0-substirutions at C28 only are accomplished in
`the same manner, but with prior protection at C40. Funher modifications are possible. For
`example, where the substituent is allyl, the isolated, monosubstituted double bond of the
`allyl moiety is highly amenable to funher modification.
`
`The 9-deoxorapamycin compounds are preferably produced by reducing a rapamycin
`using hydrogen sulfide, by reacting rapamycin with diphenyldiselenide and ttibutylphosphine
`or by other suitable reduction reaction.
`
`The 26-dihydro-rapamycins are preferably produced by reducing rapamycins or
`9-deoxorapamycins from keto to hydroxy at C26 by a mild reduction reaction, such as a
`borohydride reduction reaction.
`
`The Novel Compounds are particularly useful for the following conditions:
`
`a)
`Treatment and prevention of organ or tissue transplant rejection, e.g. for the
`treatment of recipients of e.g. heart, lung, combined heart-lung, liver, kidney, pancreatic,
`skin or corneal transplants. They are also indicated for the prevention of graft-versus-host
`disease, such as following bone marrow transplantation.
`b)
`Treatment and prevention of autoimmune disease and of inflammatory
`conditions, in particular inflammatory conditions with an etiology including an autoimmune
`
`Par Pharm., Inc.
`Exhibit 1002
`Page 019
`
`

`
`W094/09010
`
`••
`
`PCT/EP93/02604
`
`- 6-
`
`component such as anhritis (for example rheumatoid anhriris, anhritis chronica progrediente
`and anhritis deformans) and rheumatic diseases. Specific autoimmune diseases for which
`the compounds of the invention may be employed include, autoinunune hematological
`disorders (including e.g. hemolytic anaemia, aplastic anaemia, pure red cell anaemia and
`idiopathic thrombocytopenia), systemic lupus erythematosus, polychondritis, sclerodoma,
`W_egener granulamatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis,
`psoriasis, Steven-Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel
`disease (including e.g. ulcerative colitis and Crohn's disease) endocrine ophthalmopathy,
`Graves disease, sarcoidosis, multiple sclerosis, primary billiary cirrhosis, juvenile diabetes
`(diabetes mellitus type 1), uveitis (anterior and posterior), keratoconjunctivitis sicca and
`vernal keratoconjunctivitis, interstitial lung fibrosis, psoriatic anhritis, glomerulonephritis
`(with and without nephrotic syndrome, e.g. including idiopathic nephrotic syndrome or
`minimal change nephropathy) and juvenile dermatomyositis.
`c)
`Treaonent and prevention of asthma.
`d)
`Treaonent of multi-drug resistance (MDR). The Novel Compounds suppress
`P-glycoproteins (Pgp), which are the membrane transpon molecules associated with MDR.
`MDR is particularly problematic in cancer patients and AIDS patients who will not respond
`to conventional chemotherapy because the medication is pumped out of the cells by Pgp.
`The Novel Compounds are therefore useful for enhancing the efficacy of other
`chemotherapeutic agents in the treaonent and control of multidrug resistant conditions such
`as multidrug resistant cancer or multidrug resistant AIDS.
`e)
`Treaonent of proliferative disorders, e.g. rumors, hyperproliferative skin
`disorder and the like.
`Treaonent of fungal infections.
`f)
`Treaonent and prevention of inflammation, especially in potentiating the action
`
`g)
`
`of steroids.
`
`h)
`Treaonent and prevention of infection, especially infection by pathogens
`having Mip or Mip-like factors.
`i)
`Treaonent of overdoses of FK-506, rapamycin, immunosuppressive Novel
`
`1
`
`Par Pharm., Inc.
`Exhibit 1002
`Page 020
`
`

`
`W094/09010
`
`-
`
`- 7 -
`
`PCT /EP93/02604
`
`Compounds, and other macrophilin binding immunosuppressants.
`
`The invention thus provides the Novel Compounds described herein, for use as novel
`intermediates or as pharmaceuticals, methods of treating or preventing the above-described
`disorders by administering an effective amount of a Novel Compound to a patient in need
`thereof, use of a Novel Compound in the manufacture of a medicament for treattnent or
`prevention of the above-described disorders, and pharmaceutical compositions comprising a
`Novel Compound in combination or association with a pharmaceutically acceptable diluent
`or carrier.
`
`Most of the Novel Compounds described herein are highly immunosuppressive,
`especially those Novel Compounds which are 0-substituted at C40, and these Novel
`Compounds are particularly useful in indications a and b, but not in indication i. Those of
`the Novel Compounds which are less immunosuppressive, especially those which are a(cid:173)
`substituted at C28 only. are particularly useful in indications h and i, but are less preferred
`in indications a or b.
`
`The Novel Compounds are utilized by administration of a pharmaceutically effective
`dose in pharmaceutically acceptable fonn to a subject in need of treattnent. Appropriate
`dosages of the Novel Compounds will of course vary, e.g. depending on the condition to be
`treated (for example the disease type or the nature of resistance), the effect desired and the
`mode of administration.
`
`In general however satisfactory results are obtained on administration orally at
`dosages on the order of from 0.05 to 5 or up to lOmg/kglday, e.g. on the order of from 0.1
`to 2 or up to 7.5 mg/kglday administered once or, in divided doses 2 to 4x per day, or on
`administration parenterally, e.g. intravenously, for example by i.v. drip or infusion, at
`dosages on the order of from 0.01 to 2.5 up to 5 mglkglday, e.g. on the order of from 0.05
`or 0.1 up to 1.0 mg/kglday. Suitable daily dosages for patients are thus on the order of 500
`
`Par Pharm., Inc.
`Exhibit 1002
`Page 021
`
`

`
`W094/09010 •
`
`PCT /EP93/02604
`
`- 8 -
`
`mg p.o., e.g. on the order of from 5 to 100 mg p.o., or on the order of from 0.5 to 125 up to
`250 mg i.v~. e.g. on the order of from 2.5 to 50 mg i.v ..
`
`Alternatively and even preferably, dosaging is arranged in patient specific manner to
`provide pre-determined trough blood levels, e.g. as determined by RIA technique. Thus
`patient dosaging may be adjusted so as to achieve regular on-going trough blood levels as
`measured by RIA on the order of from 50 or 150 up to 500 or lOOOng/ml, i.e. analogously to
`methods of dosaging currently employed for Ciclosporin immunosuppressive therapy.
`
`The Novel Compounds may be administered as the sole active ingredient or together
`with other drugs. For example, in immunosuppressive applications such as prevention and
`treaonent of graft vs. host disease, transplant rejection, or autoimmune disease, the Novel
`Compounds may be used in combination with Ciclosporin, FK-506, or their
`immunosuppressive derivatives; corticosteroids; azathioprene; immunosuppressive
`monoclonal antibodies, e.g., monoclonal antibodies to CD3, CD4, CD25, CD28, or CD45;
`and7or other immunomodulatory compounds. For anti-inflammatory applications, the Novel
`Compounds can be used together with anti-inflammatory agents, e.g., corticosteroids. For
`anti-infective applications, the Novel Compounds can be used in combination with other
`anti-infective agents, e.g., anti-viral drugs or antibiotics.
`
`The Novel Compounds are administered by any conventional route, in particular
`enterally, e.g. orally, for example in the form of solutions for drinking, tablets or capsules or
`parenterally, for example in the form of injectable solutions or suspensions. Suitable unit
`dosage forms for oral administration comprise, e.g. from 1 to 50 mg of a compound of the
`invention, usually 1 to 10 mg. Pharmaceutical compositions comprising the novel
`compounds may be prepared analogously to pharmaceutical compositions comprising
`rapamycin, e.g., as described in EPA 0 041 795, which would be evident to one skilled in
`the art.
`
`9
`
`Par Pharm., Inc.
`Exhibit 1002
`Page 022
`
`

`
`. WO 94/09010
`
`• PCT /EP93/02604
`
`- 9 -
`
`The phannacological activity of the Novel Compounds are demonstrated in, e.g., the
`following tests:
`
`1. Mixed lvmphocvte reaction (Ml..R)
`The Mixed Lymphocyte Reaction was originally developed in connection with
`allografts, to assess the tissue compatibility between potential organ donors and recipients,
`and is one of the best established models of immune reaction in vitro. A murine model
`MLR, e.g., as described by T.Meo in "Immunological Methods", L. Lefkovits and B. Peris,
`Eds., Academic Press, N.Y. pp. 227-239 (1979), is used to demonstrate the
`immunosuppressive effect of the Novel Compounds. Spleen cells (0.5 x 106
`) from Balb/c
`mice (female, 8-10 weeks) are co-incubated for 5 days with 0.5 x 106 irradiated (2000 rads)
`or mitomycin C treated spleen cells from CBA mice (female, 8-10 weeks). The irradiated
`allogeneic cells induce a proliferative response in the Balb/c spleen cells which can be
`measured by labeled precursor incorporation into the DNA. Since the stimulator cells are
`irradiated (or mitomycin C treated) they do not respond to the Balb/c cells with proliferation
`but do retain their antigenicity. The anti proliferative effect of the Novel Compounds on the
`Balb/c cells is measured at various dilutions and the concentration resulting in 50%
`inhibition of cell proliferation (IC~0) is calculated. The inhibitory capacity of the test sample
`may be compared to rapamycin and expressed as a relative IC~0 (i.e. IC~0 test sample/IC50
`rapamycin).
`
`2.
`
`IL-6 mediated proliferation
`The capacity of the Novel Compounds to interfere with growth factor associated
`signalling pathways is assessed using an interleukin-6 (Il...-6)-dependent mouse hybridoma
`cell line. The assay is performed in 96-well microtiter plates. 5000 cells/well are cultivated
`in serum-free medium (as described by M. H. Schreier and R. Tees in Immunological
`Methods, I. Lefkovits and B. Pemis, eds., Academic Press 1981, VoL II, pp. 263-275),
`supplemented with 1 ng recombinant ll...-6/ml. Following a 66 hour incubation in the
`absence or presence of a test sample, cells are pulsed with 1 JJCi (3-H)-thymidine/well for
`
`;o.
`
`Par Pharm., Inc.
`Exhibit 1002
`Page 023
`
`

`
`wo 94/09010 •
`
`Per /EP93/02604
`
`- 10-
`
`another 6 hours, harvested and counted by liquid scintillation. (3-H)-thymidine incorporation
`into DNA correlates with the increase in cell number and is thus a measure of cell
`proliferation. A dilu

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket